Clinical Trials
8
Active:0
Completed:8
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (50.0%)Phase 1
2 (25.0%)Phase 2
2 (25.0%)A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT02173249
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Phase 3
Completed
- Conditions
- Atopic Disease (Including Allergic Conjunctivitis)
- Interventions
- Drug: AC-170 0%
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 512
- Registration Number
- NCT02132169
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0.24%Drug: AC-170 0%
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01881113
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0%Drug: AC-170 0.24%
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01685242
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: AC-170 0%Drug: AC-170 0.24%
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Aciex Therapeutics, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01551056
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
No news found